BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012;26:1408-1416. [PMID: 22495621 DOI: 10.1177/0269881112441866] [Cited by in Crossref: 74] [Cited by in F6Publishing: 59] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Faquih AE, Memon RI, Hafeez H, Zeshan M, Naveed S. A Review of Novel Antidepressants: A Guide for Clinicians. Cureus 2019;11:e4185. [PMID: 31106085 DOI: 10.7759/cureus.4185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
2 Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar AR. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder: Vortioxetine for major depression. Psychiatry Clin Neurosci 2018;72:64-72. [DOI: 10.1111/pcn.12565] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
3 Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014;19:121-33. [PMID: 23903233 DOI: 10.1017/S1092852913000540] [Cited by in Crossref: 91] [Cited by in F6Publishing: 30] [Article Influence: 11.4] [Reference Citation Analysis]
4 Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacology & Therapeutics 2015;145:43-57. [DOI: 10.1016/j.pharmthera.2014.07.001] [Cited by in Crossref: 245] [Cited by in F6Publishing: 183] [Article Influence: 40.8] [Reference Citation Analysis]
5 Christensen MC, Florea I, Loft H, McIntyre RS. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. J Affect Disord 2020;263:258-66. [PMID: 31818787 DOI: 10.1016/j.jad.2019.11.074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Jacobsen P, Zhong W, Xu R, Nomikos G. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study. J Affect Disord 2020;266:173-81. [PMID: 32056873 DOI: 10.1016/j.jad.2020.01.090] [Reference Citation Analysis]
7 Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Buonaguro EF, Vellante F, Fornaro M, Fiengo A, Mazza M, Vecchiotti R, Perna G, de Bartolomeis A, Martinotti G, Di Giannantonio M, De Berardis D. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Rev Neurother 2016;16:483-95. [PMID: 27050932 DOI: 10.1586/14737175.2016.1173545] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
8 Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 2015;23:1-21. [PMID: 25643025 DOI: 10.1037/a0038550] [Cited by in Crossref: 172] [Cited by in F6Publishing: 128] [Article Influence: 28.7] [Reference Citation Analysis]
9 Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68:60-82. [PMID: 24165478 DOI: 10.1111/ijcp.12350] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
10 Cosgrove L, Vannoy S, Mintzes B, Shaughnessy AF. Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation. Accountability in Research 2016;23:257-79. [DOI: 10.1080/08989621.2016.1153971] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]
11 Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother 2014;15:2525-42. [PMID: 25224953 DOI: 10.1517/14656566.2014.960842] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
12 Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. J Sex Med 2015;12:2036-48. [PMID: 26331383 DOI: 10.1111/jsm.12980] [Cited by in Crossref: 45] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
13 Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015;14:1291-304. [PMID: 26022537 DOI: 10.1517/14740338.2015.1046836] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
14 Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl) 2015;232:2061-70. [PMID: 25575488 DOI: 10.1007/s00213-014-3839-0] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
15 Köhler S, Cierpinsky K, Kronenberg G, Adli M. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. J Psychopharmacol 2016;30:13-22. [DOI: 10.1177/0269881115609072] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 14.6] [Reference Citation Analysis]
16 Soini E, Hallinen T, Brignone M, Campbell R, Diamand F, Cure S, Aalto-setälä M, Danchenko N, Koponen H, Kolasa K. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert Review of Pharmacoeconomics & Outcomes Research 2017;17:293-302. [DOI: 10.1080/14737167.2017.1240617] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
17 Durgam S, Chen C, Migliore R, Prakash C, Thase ME. Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. Depress Anxiety 2019;36:225-34. [PMID: 30675739 DOI: 10.1002/da.22872] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Gibb A, Deeks ED. Vortioxetine: First Global Approval. Drugs 2014;74:135-45. [DOI: 10.1007/s40265-013-0161-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
19 Connolly KR, Thase ME. Vortioxetine: a New Treatment for Major Depressive Disorder. Expert Opinion on Pharmacotherapy 2016;17:421-31. [DOI: 10.1517/14656566.2016.1133588] [Cited by in Crossref: 36] [Cited by in F6Publishing: 19] [Article Influence: 7.2] [Reference Citation Analysis]
20 Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014;29:138-149. [PMID: 24257717 DOI: 10.1097/yic.0000000000000018] [Cited by in Crossref: 102] [Cited by in F6Publishing: 29] [Article Influence: 14.6] [Reference Citation Analysis]
21 Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013;16:313-321. [PMID: 22963932 DOI: 10.1017/s1461145712000727] [Cited by in Crossref: 77] [Cited by in F6Publishing: 24] [Article Influence: 8.6] [Reference Citation Analysis]
22 Salagre E, Grande I, Solé B, Sanchez-Moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment (Engl Ed) 2018;11:48-59. [PMID: 28800937 DOI: 10.1016/j.rpsm.2017.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
23 Carta MG, Pala AN, Finco G, Musu M, Moro MF. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? Clin Pract Epidemiol Ment Health 2015;11:144-9. [PMID: 25893002 DOI: 10.2174/1745017901511010144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Dubovsky SL. Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder. Expert Opin Drug Metab Toxicol 2014;10:759-66. [PMID: 24684240 DOI: 10.1517/17425255.2014.904286] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
25 Dale E, Bang-andersen B, Sánchez C. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology 2015;95:81-97. [DOI: 10.1016/j.bcp.2015.03.011] [Cited by in Crossref: 123] [Cited by in F6Publishing: 103] [Article Influence: 20.5] [Reference Citation Analysis]
26 Refsgaard LK, Haubro K, Pickering DS, Stuart SA, Robinson ESJ, Andreasen JT. Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test. Psychopharmacology 2016;233:3763-70. [DOI: 10.1007/s00213-016-4407-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
27 Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder: EFFICACY AND TOLERABILITY OF TWO VORTIOXETINE DOSES IN ACUTE GAD. Hum Psychopharmacol Clin Exp 2014;29:64-72. [DOI: 10.1002/hup.2371] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
28 Fu J, Chen Y. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis. Psychopharmacology (Berl) 2015;232:7-16. [PMID: 24871704 DOI: 10.1007/s00213-014-3633-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
29 Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ; Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry 2015;16:76-95. [PMID: 25677972 DOI: 10.3109/15622975.2014.1001786] [Cited by in Crossref: 102] [Cited by in F6Publishing: 73] [Article Influence: 17.0] [Reference Citation Analysis]
30 Katona CL, Katona CP. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat 2014;10:349-54. [PMID: 24570588 DOI: 10.2147/NDT.S39544] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]
31 Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM, McInerney SJ, McIntosh D, Milev RV, Müller DJ, Parikh SV, Pearson NL, Ravindran AV, Uher R; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry 2016;61:540-60. [PMID: 27486148 DOI: 10.1177/0706743716659417] [Cited by in Crossref: 357] [Cited by in F6Publishing: 272] [Article Influence: 71.4] [Reference Citation Analysis]
32 Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, Hopwood M, Lyndon B, Mulder R, Murray G, Porter R, Singh AB. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015;49:1087-206. [DOI: 10.1177/0004867415617657] [Cited by in Crossref: 414] [Cited by in F6Publishing: 287] [Article Influence: 69.0] [Reference Citation Analysis]
33 Tritschler L, Felice D, Colle R, Guilloux J, Corruble E, Gardier AM, David DJ. Vortioxetine for the treatment of major depressive disorder. Expert Review of Clinical Pharmacology 2014;7:731-45. [DOI: 10.1586/17512433.2014.950655] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
34 Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014;28:855-74. [PMID: 25145538 DOI: 10.1007/s40263-014-0195-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
35 Baldwin DS, Nutt DJ. On assessing potential efficacy for vortioxetine in generalized anxiety disorder. European Neuropsychopharmacology 2012;22:841-3. [DOI: 10.1016/j.euroneuro.2012.07.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
36 Jacobsen P, Zhong W, Nomikos G, Clayton A. Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial. J Sex Med 2019;16:1638-49. [PMID: 31405765 DOI: 10.1016/j.jsxm.2019.06.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
37 Sim K, Lau WK, Sim J, Sum MY, Baldessarini RJ. Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials. Int J Neuropsychopharmacol 2015;19:pyv076. [PMID: 26152228 DOI: 10.1093/ijnp/pyv076] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 9.7] [Reference Citation Analysis]
38 Pearce EF, Murphy JA. Vortioxetine for the treatment of depression. Ann Pharmacother 2014;48:758-65. [PMID: 24676550 DOI: 10.1177/1060028014528305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
39 Bobo W, Kelliny M, Croarkin P, Moore K. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. TCRM. [DOI: 10.2147/tcrm.s55313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
40 Leiser SC, Pehrson AL, Robichaud PJ, Sanchez C. Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats. Br J Pharmacol 2014;171:4255-72. [PMID: 24846338 DOI: 10.1111/bph.12782] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
41 Van Leeuwen E, van Driel ML, Horowitz MA, Kendrick T, Donald M, De Sutter AI, Robertson L, Christiaens T. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database Syst Rev 2021;4:CD013495. [PMID: 33886130 DOI: 10.1002/14651858.CD013495.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
42 Kennedy SH. A review of antidepressant therapy in primary care: current practices and future directions. Prim Care Companion CNS Disord 2013;15:PCC. [PMID: 23930234 DOI: 10.4088/PCC.12r01420] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
43 Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014;29:470-82. [PMID: 25087600 DOI: 10.1002/hup.2424] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 11.5] [Reference Citation Analysis]
44 Vieta E, Loft H, Florea I. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder. European Neuropsychopharmacology 2017;27:877-84. [DOI: 10.1016/j.euroneuro.2017.06.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
45 Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C. Vortioxetine for depression in adults. Cochrane Database Syst Rev 2017;7:CD011520. [PMID: 28677828 DOI: 10.1002/14651858.CD011520.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
46 Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord 2018;227:803-9. [PMID: 29673132 DOI: 10.1016/j.jad.2017.11.053] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 5.8] [Reference Citation Analysis]
47 Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2014;10:1297-307. [PMID: 25075188 DOI: 10.2147/NDT.S41387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 5.4] [Reference Citation Analysis]
48 Roman MW, Wilkinson SM. Vortioxetine (Brintellix ® ) and Levomilnacipran (Fetzima ® ): The Two Newest Additions to the Antidepressant Formulary. Issues in Mental Health Nursing 2014;35:972-4. [DOI: 10.3109/01612840.2014.955155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Baldessarini RJ, Lau WK, Sim J, Sum MY, Sim K. Suicidal Risks in Reports of Long-Term Controlled Trials of Antidepressants for Major Depressive Disorder II. Int J Neuropsychopharmacol 2017;20:281-4. [PMID: 28003313 DOI: 10.1093/ijnp/pyw092] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
50 Deardorff WJ, Grossberg GT. The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly. Curr Geri Rep 2015;4:301-11. [DOI: 10.1007/s13670-015-0140-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Subeesh V, Singh H, Maheswari E, Beulah E. Novel adverse events of vortioxetine: A disproportionality analysis in USFDA adverse event reporting system database. Asian J Psychiatr 2017;30:152-6. [PMID: 28942181 DOI: 10.1016/j.ajp.2017.09.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
52 Kato M, Hori H, Inoue T, Iga J, Iwata M, Inagaki T, Shinohara K, Imai H, Murata A, Mishima K, Tajika A. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry 2021;26:118-33. [PMID: 32704061 DOI: 10.1038/s41380-020-0843-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
53 Mahableshwarkar AR, Jacobsen PL, Chen Y, Simon JS. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder. Int J Clin Pract 2014;68:49-59. [DOI: 10.1111/ijcp.12328] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
54 Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci 2015;40:174-86. [PMID: 25350320 DOI: 10.1503/jpn.140120] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
55 Zhou D, Lv Z, Shi L, Zhou X, Lin Q, Chen X, Wan L, Li Y, Ran L, Huang Y, Wang G, Li D, Wang W, Liu C, Kuang L. Effects of antidepressant medicines on preventing relapse of unipolar depression: a pooled analysis of parametric survival curves. Psychol Med . [DOI: 10.1017/s0033291720001610] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Mills NT, Sampson E, Fourrier C, Baune BT. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial. Int J Neuropsychopharmacol 2021;24:314-21. [PMID: 33269395 DOI: 10.1093/ijnp/pyaa092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Citrome L, Dibernardo A, Singh J. Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 2020;271:228-38. [DOI: 10.1016/j.jad.2020.03.106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
58 McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat 2017;13:2913-9. [PMID: 29238196 DOI: 10.2147/NDT.S150589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
59 François C, Nielsen R, Danchenko N, Williams V, Lançon C. The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine. Current Medical Research and Opinion 2017;33:1057-66. [DOI: 10.1080/03007995.2017.1299701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]